Petreska, Bojana
Preferred name
Petreska, Bojana
Official Name
Petreska, Bojana
Translated Name
Петреска, Бојана
Main Affiliation
Email
bojanapetreska@gmail.com
9 results
Now showing 1 - 9 of 9
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia(ID Design 2012/Scienfitic Foundation SPIROSKI, 2017-12-15); ; ; ; The primary objective of the study was to evaluate the overall survival of women with advanced stage (Stage IIIA-IV) high-grade serous ovarian cancer in Macedonia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multimodality treatment of brain metastases from ovarian cancer(Macedonian Association of Pathology, 2016-09); ; ; Objective: Brain metastases from ovarian cancer are uncommon and usually associated with mean survival less than 12 months. In some cases, multimodality treatment may achieve an improved outcome in these patients. Material and Methods: Two cases of multiple brain metastases from ovarian cancer are presented. A combination of whole-brainradiotherapy (WBRT) and chemotherapy (Topotecan) was used. Results: Case 1: A 62-year-old patient was diagnosed and treated for primary ovarian cancer in 2012. She underwent optimal surgical resection and adjuvant platinum-based chemotherapy (Carboplatin/Paclitaxel, 6 cycles). Eleven months after the initial treatment the patient developed right hemiparesis. Brain CT documented multiple brain metastases in the left frontal and parietal lobe. She proceeded to WBRT and subsequent 4 cycles of Topotecan. At a follow-up of 24 months, there is no evidence of recurrent disease. Case 2: A 63-year-old patient was diagnosed with primary ovarian cancer in 2012. Initially, she received neoadjuvant chemotherapy (Carboplatin/Paclitaxel, 6 cycles and Doxorubicin/Carboplatin, 3 cycles) followed by surgical treatment. After 1-year follow-up, multiple brain metastases in the right temporoparietal and occipital lobe were detected by brain MRI. She underwent WBRT followed by 4 cycles of Topotecan. Better motor performance was achieved and the MRI scan evaluation showed volume reductions of brain metastases. Nine months later, CT scan revealed a progression of the metastatic disease and re-WBRT was performed. At a follow-up of 18 months, she is in good clinical condition. Conclusions: In ovarian cancer patients with multiple brain metastases, multimodal therapeutic approach including radiotherapy followed by chemotherapy may lead to prolonged survival. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PROGNOSTIC VALUE OF MOLECULAR MARKER ON OUTCOME IN PATIENTS WITH HIGH-GRADE GLIOMA. SINGLE INSTITUTIONAL EXPERIENCE(Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2020-10); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A SINGLE INSTITUTIONAL EXPERIENCE WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER(Sestre milosrdnice University Hospital Center University Hospital for Tumors, Zagreb, Croatia, 2022-05); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Adjuvant chemotherapy and radiotherapy for Stage III endometrial cancer: Impact on Survival(RAD Association, 2018-06); ; ; Introduction. Adjuvant treatment options for advanced-stage endometrial cancer include chemotherapy (CT) and radiation therapy (RT), but the optimal treatment strategy is currently under debate. The aim of this study is to investigate the utilization of adjuvant RT and CT in patients with stage III endometrial cancer and their impact on overall survival (OS) and disease-free survival (DFS). Materials and Methods. A retrospective review was performed of 40 patients with Stage III endometrial cancer who received adjuvant treatment at University Clinic of Radiotherapy and Oncology (UCRO) in Skopje between 2012 and 2015. Postoperative treatment was administered based on performance status and medical comorbidities. Chemotherapy regimens comprised of Carboplatin (AUC 5) and Paclitaxel (175 mg/m2), a 3-week interval for 6 cycles (chemotherapy alone) and 4 cycles (sequential arm). RT was delivered using 3-D CRT with a total dose of 50 Gy in 25 fractions prescribed in PTV for 5 weeks with/without an additional 7 Gy prescribed at a depth of 0.5 cm from the vaginal surface. The primary endpoints were overall survival (OS) and disease-free survival (DFS). Combined radiotherapy and chemotherapy were compared with radiotherapy alone and chemotherapy alone. Results. The distribution of surgical stages is as follows: IIIA accounted for 60% (n=24), stage IIIB accounted for 9.8% (n=4) and stage IIIC accounted for 30% (n=12). The median age was 65 years and median follow-up was 35.5 months. There were 40 patients who received adjuvant treatment, 10% (n=4) received CT alone, 27.5% (n=11) received RT alone, and 62.5% (n=25) received sequential combined CT followed by 3D CRT with/without vaginal vault brachytherapy. Relapse occurred in 55% (n=22) of the patients. High grade and lymphovascular space invasion (LVSI) are risk factors for recurrence and poor prognosis. Overall survival (OS) and Disease-free survival (DFS) at 3 years for patients receiving combined CT and RT, adjuvant RT alone and adjuvant CT alone were 68.8%, 41.26%, and 37.57% for OS and 58.03%, 33.08%, and 24.96% for DFS, respectively. DFS and OS were significantly longer in patients treated with combined RT and CT than in those treated with CT alone (DFS: p= 0.0005; hazard ratio [HR], 5.677; OS: p= 0.0143; HR, 4.289) or RT alone (DFS: p = 0.0137; HR, 2.482; OS: p = 0.0151; HR, 3.036). Conclusion. Combined modality treatment with chemotherapy and radiotherapy can improve both overall and disease-free survival in patients with Stage III endometrial cancer compared with single modality alone. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Adjuvant chemotherapy in patients with stage IIIA endometrial carcinoma with solitary adnexal involvement(Macedonian Association of Pathology, 2016-09); ; ; Objective: The optimal adjuvant therapy in endometrial cancer patients with solitary adnexal involvement is still controversial. The purpose of this study was to evaluate, retrospectively, the outcome and efficacy of adjuvant chemotherapy in these patients. Material and Methods: The medical records of the patients with stage IIIA endometrial cancer with solitary adnexal involvement who were treated with surgical resection and adjuvant chemotherapy between 2005 and 2010, were retrospectively analyzed. A total of 40 patients treated with platinum-based adjuvant chemotherapy were included. Following surgery, all patients received 4 cycles of Carboplatin 300 mg/m2 and Paclitaxel 175 mg/m2 by intravenous injection every 3 weeks. The survival and recurrence rates were evaluated. Results: The median follow-up period was 5 years (60 months). Recurrences occurred in 12.5 % (n=5) of the patients. One local recurrence (1/5, 20%) and 4 distant metastases (4/5, 80%) in liver (n=2, 40%), lung (n=1, 20%) and paraaortal lymph nodes (n=1, 20%) were observed. The 3-year disease-free survival (DFS) and overall survival (OS) rates were 87.5% and 92.3%, respectively. Conclusions: In conclusion, platinum-based adjuvant chemotherapy may improve prognosis and survival in stage IIIA endometrial cancer patients with solitary adnexal involvement and could be considered as a potential adjuvant treatment. Although adjuvant chemotherapy has demonstrated improved both disease-fee and overall survival compared to radiotherapy (DFS 87.5% vs 69%; OS 92.3% vs 78%), further studies are needed to define the optimal treatment strategy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Planning study of comparison of dose in target volumes and volumes of organs at risk in patients with high grade glioma. Intensity Modulated Radiotherapy versus Three- dimensional Conformal radiotherapy (3D-CRT)(International Atomic Energy Agency, 2017); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RELATIONSHIP BETWEEN O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND TUMOR SIZE ON PREOPERATIVE CONTRAST ENHANCED MRI IN PATIENTS WITH GLIOBLASTOMA MULTIFORME – SINGLE INSTITUTION EXPERIENCE(RAD Association, 2018-06-01); ; ; Bojovska, ValentinaIntroduction. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is considered as an important prognostic marker in patients with glioblastoma multiforme. Patients with methylated MGMT promoter are considered that have better prognosis, have longer disease free survival and overall survival. Methods. We performed retrospective analysis of 28 patients with glioblastoma multiforme intended to be treated with radiotherapy and with known MGMT promoter status. Volume of the tumor was measured on initial MR of the brain and it was delineated on transversal MR image DICOM datasets. “Tumor” was defined as contrast enhanced region in T1 weighted image after application of i.v. contrast. Results. From 28 patients, 14 patients were with methylated MGMT promotor (MGMT-M) and 14 with wild type MGMT promotor (MGMT-W). Mean MRI tumor volume in MGMT-M group was 45.41 cm3 (range 4.50 cm3 – 95.26 cm3) and in MGMT-W group 50.46 cm3 (range 3.81 cm3 – 134.79 cm3). Comparison of volumes of 2 groups has shown that there are no significant differences between tumor volumes in the groups p= 0.29864. Conclusion. In our study we can conclude that there is no correlation between MGMT methylation status and initial tumor volume in patients with glioblastoma multiforme. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact on dose and volume on irradiated brain on recurrence and survival of patients with glioblastoma multiformae(International Atomic Energy Agency, 2017-06); ;